C11275: Novel Method to Restore Synchronous Contraction in Heart FailureNovelty:
This technology provides a pharmacological approach to mimic Cardiac Resynchronization Therapy (CRT) without artificial electric stimulation.
Value Proposition:
This invention provides potential improvement in heart failure patients whose hearts are synchronous or dyssynchronous. Other advantages include:
• Apply to all patients for which the pacing therapy is presently not available.
.
• Apply to non-CRT qualified patients (about 75%), patients with weak response to CRT, and potentially yield a even better response for patients who shows strong response to CRT.
.
• Improves the performance of conventional CRT – by providing rest periods from resynchronization.
• Easily integrated to existing technologies (e.g. pacemakers/defibrillator units) used by patients.
.
Technical Details:
Johns Hopkins researchers have discovered a new method to effectively treat heart failure patients with synchronous contractions using CRT. This invention utilizes a system with automatic switch between dyssynchronous and synchronous pacing modes in patients receiving pacemakers, defibrillators, or CRT devices with or without an internal defibrillator. The mode of use could vary widely depending on the clinical data, including dyssynchrony pacing for a period of hours, days, weeks, or months, followed by resynchronization for a variable length of time; this may be repeated as continuous therapy, or the time-frame for the two models altered. Programming features would apply to existing commercial pacemaker and defibrillator units, and are not exclusive to any manufacturer of a pacing or internal defibrillator device. Therefore, inducing dyssynchrony for limited periods of time in patients whose hearts are otherwise not dyssynchronous, and then restoring synchrony by either bi-ventricular pacing or reversion to normal native electrical conduction, will provide improvement in heart failure function and clinical symptoms.
Looking for Partners:
To develop & commercialize the technology as a treatment for heart failure patients with synchronous and dyssynchronous contractions.
Stage of Development:
Pre-clinical
Data Availability:
Animal (canine) data available with striking evidence that the present technology may reduce mortality and morbidity associated with heart failure.
Publications/Associated Cases:
Not available at this time
